Invivyd (IVVD) Current Assets (2020 - 2026)
Invivyd's (IVVD) quarterly Current Assets came in at $182.1 million in Q2 2026, up 207.2% on a YoY basis from $59.3 million in Q2 2025, and down 26.41% quarter-over-quarter from $247.5 million in Q4 2025.
Analysis
Invivyd (IVVD) Current Assets (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Current Assets for 7 consecutive years, with $182.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Assets rose 207.2% year-over-year to $182.1 million; the trailing twelve-month figure through Jun 2026 stood at $182.1 million (up 207.2% YoY), and the FY2025 full-year result was $247.5 million, up 145.79% from the prior year.
- Current Assets declined to $182.1 million in Q2 2026 per IVVD's latest filing, from $247.5 million in the prior quarter.
- Across five years, Current Assets topped out at $554.3 million in Q1 2022 and bottomed at $59.3 million in Q2 2025.
- Historically, Current Assets has averaged $252.5 million across 5 years, with a median of $224.9 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Current Assets sank 65.74% in 2025, then surged 207.2% in 2026.
- Over 5 years, Current Assets stood at $376.9 million in 2022, then plunged by 40.34% to $224.9 million in 2023, then slumped by 55.23% to $100.7 million in 2024, then surged by 145.79% to $247.5 million in 2025, then fell by 26.41% to $182.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $182.1 million, $247.5 million, and $109.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 182.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 182.11 Mn |
| Dec 31, 2025 | 247.47 Mn |
| Sep 30, 2025 | 109.77 Mn |
| Jun 30, 2025 | 59.28 Mn |
| Mar 31, 2025 | 75.83 Mn |
| Dec 31, 2024 | 100.68 Mn |
| Sep 30, 2024 | 151.10 Mn |
| Jun 30, 2024 | 173.01 Mn |
| Mar 31, 2024 | 209.88 Mn |
| Dec 31, 2023 | 224.88 Mn |
| Sep 30, 2023 | 270.10 Mn |
| Jun 30, 2023 | 309.99 Mn |
| Mar 31, 2023 | 344.62 Mn |
| Dec 31, 2022 | 376.92 Mn |
| Sep 30, 2022 | 421.60 Mn |
| Jun 30, 2022 | 481.36 Mn |
| Mar 31, 2022 | 554.30 Mn |
| Dec 31, 2021 | 616.71 Mn |
| Sep 30, 2021 | 680.16 Mn |
| Jun 30, 2021 | 396.06 Mn |